{
    "2021-09-27": [
        [
            {
                "time": "",
                "original_text": "白雲山抗結核藥物吡嗪酰胺片通過一致性評價",
                "features": {
                    "keywords": [
                        "白雲山",
                        "吡嗪酰胺片",
                        "一致性評價",
                        "抗結核藥物"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "白雲山子公司抗結核藥過評！",
                "features": {
                    "keywords": [
                        "白雲山",
                        "子公司",
                        "抗結核藥",
                        "過評"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "白雲山：藥品吡嗪酰胺片通過仿製藥一致性評價",
                "features": {
                    "keywords": [
                        "白雲山",
                        "吡嗪酰胺片",
                        "仿製藥",
                        "一致性評價"
                    ],
                    "sentiment_score": 0.88,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "白雲山：全資子公司吡嗪酰胺片已通過仿製藥質量和療效一致性評價",
                "features": {
                    "keywords": [
                        "白雲山",
                        "全資子公司",
                        "吡嗪酰胺片",
                        "仿製藥",
                        "質量",
                        "療效",
                        "一致性評價"
                    ],
                    "sentiment_score": 0.92,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "醫藥"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}